Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation

Circulation

Volumn 94, Issue 7, 1996, Pages 1613-1621

  Stambler, Bruce S ^a   Wood, Mark A ^b   Ellenbogen, Kenneth A ^b   Perry, Kimberly T ^c   Wakefield, Linda K ^c   VanderLugt, James T ^c  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b Veterans Administration   (United States)

^c PFIZER INC   (United States)

Author keywords

antiarrhythmia agents; arrhythmia; atrial flutter; fibrillation; ibutilide

Indexed keywords

IBUTILIDE FUMARATE;

ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM;

EID: 0029778315     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.7.1613     Document Type: Article

References (48)

1. Fenster PE, Comess KA, Marsh R, Katzenberg C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J. 1983;106:501-504.
2. Halpern SW, Ellrodt G, Singh BN, Mandel WJ. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm. Br Heart J. 1980;44:589-595.
3. Madrid A, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J. 1993;14:1127-1131.
4. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation in the Wolff-Parkinson-White Syndrome by procainamide and propafenone. J Am Coll Cardiol. 1990; 16:1408-1414.
5. Olshansky B, Okumara K, Hess PG, Henthorn RW, Waldo AL. Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. J Am Coll Cardiol 1988;11:359-364.
6. Suttorp MJ, Kingma JH, Jessurun ER, Lie-A-Huen L, Van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16:1722-1727.
7. Vita JA, Friedman PL, Cantillon C, Antman EM. Efficacy of intravenous propafenone for the acute management of atrial fibrillation. Am J Cardiol. 1989;63:1275-1278.
8. Bianconi L, Boccadamo R, Pappalardo A, Gentilli C, Pistolese M. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol. 1989;64:335-338.
9. Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol. 1989; 63:693-696.
10. Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 1986;58:496-498.
11. Hellestrand KJ. Intravenous flecainide for supraventricular tachycardias. Am J Cardiol. 1988;62:16D-22D.
12. Faniel R, Schoenfeld PH. Efficacy of IV amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart J. 1983;4:180-185.
13. Strasberg B, Arditti A, Sclarovsky S, Lewin RF, Buimovici B, Agmon J. Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. Int J Cardiol. 1985;7:47-58.
14. Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY. Intra-venous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 1995;75:693-697.
15. Bianconi L, Dinelli M, Pappalardo A, Richiardi E, Castro A, Alboni P, Santini M, Dalrymple HW, Radula D. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. Circulation. 1995;92:774. Abstract.
16. Sung RJ, Tan HL, Karagounis L, Hanyok JJ, Falk R, Platia E, Das G, Hardy SA. Intravenous sotalol for the termination of supraven-tricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J. 1995;129:739-748.
17. Buchanan LV, Kabell GG, Gibson JK. Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents. J Cardiovasc Pharmacol. 1995;25:539-544.
18. Buchanan LV, Turcotte VM, Kabell GG, Gibson JK. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol. 1993;33:10-14.
19. Nabih MA, Prcevski P, Fromm BS, Lavine SJ, Elnabtity M, Munir A, Steinman RT, Meissner MD, Lehmann MH. Effect of ibutilide, a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. PACE. 1993;16:1975-1983.
20. Ellenbogen KA, Wood MA, Stambler BS, Wakefield LK, Vander-Lugt JT. Conversion of atrial fibrillation and flutter by intravenous ibutilide: a multicenter dose response study. J Am Coll Cardiol. 1994;227A. Abstract.
21. Manning WJ, Silverman DI, Katz SE, Riley MF, Doherty RM, Munson JT, Douglas PS. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 1995;75:624-626.
22. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. Circulation. 1995;92:1954-1968.
23. Hohnloser SH, Andreas L, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 1995;26:852-858.
24. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med. 1989;111: 107-111.
25. Feld GK, Chen PS, Nicod P, Fleck RP, Mezer D. Atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol. 1990;66:378-383.
26. Singh BN, Sarma JSM, Zhang ZH, Takanaka C. Controlling cardiac arrhythmias by lengthening repolarization: rationale from experimental findings and clinical considerations. Ann N Y Acad Sci. 1992; 644:187-209.
27. Cimini MG, Brunden MN, Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol. 1992;222:93-98.
28. Hester JB, Gibson JK, Cimini MG, Emmert DE, Locker PK, Perricone SC, Skaletzky LL, Sykes JK, West BE. N-[(ω-amino-1-Hydroxyalkyl)phenyl]methansulfonamide derivatives with class III antiarrhythmic activity. J Med Chem. 1991;34:308-315.
29. + current in guinea pig ventricular cells. J Pharmacol Exp Ther. 1992;262:99-108.
30. Lee KS, Tsai TD, Lee EW. Membrane activity of class III antiarrhythmic compounds: a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. Eur J Pharmacol. 1993;234:43-53.
31. kr) in AT-1 cells. Circulation. 1995;91;1799-1806.
32. DiMarco JP, The Ibutilide for Atrial Arrhythmias Study Group. Cardioversion of atrial flutter by intravenous ibutilide, a new class III antiarrhythmic agent. J Am Coll Cardiol. 1991;17:324A. Abstract.
33. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harigan P, Hughes RA, Weyman A. Atrial enlargement as a consequence of atrial fibrillation. Circulation. 1990;82:792-797.
34. Allessie MA. Reentrant mechanisms underlying atrial fibrillation. In: Zipes DP, Jalife, J eds. Electrophysiology: From Cell to Bedside. 2nd Ed. Philadelphia, Pa: WB Saunders; 1995;562-566.
35. Rensma PL, Allessie MA, Lammers WJEP, Bonke FIM, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res. 1988;62:395-410.
36. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on ar-rhythmogenic mechanisms. Circulation. 1991;84:1831-1851.
37. Olshansky B, Wilber DJ, Hariman RA. Atrial flutter: update on the mechanism and treatment. PACE. 1992;15:2308-2336.
38. Boyden PA, Graziano JN. Activation mapping of reentry around an anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol. J Cardiovasc Electrophysiol. 1993;4:266-279.
39. Wit AL, Coromilas J. Role of alterations in refractoriness and conduction in the genesis of reentrant arrhythmias. Am J Cardiol. 1993;72:3F-12F.
40. Feld GK, Venkatesh N. Singh BN. Pharmacological conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction. Circulation. 1986;74:197-204.
41. Feld GK, Venkatesh N, Singh BN. Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction. J Cardiovasc Pharmacol. 1988;11:573-580.
42. Wang J, Bourne G, Wang Z, Villemaire C, Talajic M, Nattel S. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Circulation. 1993;88:1030-1044.
43. Wang Z, Page P, Nattel S. The mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res. 1992; 71:271-287.
44. Ben-David J, Zipes D. Torsade de pointes and proarrhythmia. Lancet. 1993;341:1578-1582.
45. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088-1093.
46. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol. 1993;72: 44A-50A.
47. Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, Janosik DL, Kopelman HA, Scheinman MM, for the Intravenous Amiodarone Multicenter Investigators Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation. 1995;92:3255-3263.
48. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, Platia EV, Wilber DJ, Kowey PR, for the Intra-venous Amiodarone Multicenter Investigators Group. Dose-ranging study of intravenous amiodarone in patients with life-threatening ven-tricular tachyarrhythmias. Circulation. 1995;92:3264-3272.